Dr. Valerio Di Nicola is Lead of the Paediatric Surgery of the Noble’s Hospital- Isle of Man (UK). He was born in Rome, and graduated in Medicine in 1989. From 1989 until 1997 he worked in Policlinico Umberto I in Rome first as Resident during his General Surgery Residency and then, during his PhD in Microsurgery, he worked as Researcher. In the next years he improved his skills in Laparoscopic and Minimally Invasive procedures (Fellowship of ACOI- Italian Surgeons Association) and increased his knowledge in Coloproctology with a Fellowship in Oncological Colorectal Minimally Invasive and Open Surgery. Later he achieved a Master in Coloproctology at the University ‘La Sapienza’of Rome. From 2006 to January 2010 Dr. Nicola was Consultant of the General Surgery Department at San Marco Hospital in Latina, Italy. From January 2010 he was Consultant of General and Colorectal Surgery at the Israelite Hospital of Rome. From Nov. 2010 to June 2013 he had worked as Consultant, at the General Surgery and Emergency Department (DEAI) of the Aurelia Hospital in Rome. On May 2013, he has been appointed Scientific Director of Interbion Foundation for Basic Biomedical Research. Montedato, CH-6595 Riazzino, Switzerland (www.interbion.org). From July, 08, 2013 he has been working at Noble’s Hospital- Isle of Man (UK), in the General Surgery Department, as a Consultant in General and Colorectal Surgery. Since September 2015 he has been the Coordinator for the Wednesday Teaching Surgical meetings for the Noble’s junior Doctors. On December 2015 he was appointed Lead of the Paediatric Surgery of the Noble’s Hospital- Isle of Man (UK). In the last eighteen years parallel with his surgical activities Dr. Nicola has been working on Regenerative Medicine. In the last 15 years he has developed in his own private clinic a new approach to stimulate and activate innate joint stem cells forming a favourable micro-environment in the area of joint degeneration apt to promote tissue regeneration. In his Clinic, he has been studying and treating ultraoctogenarian patients always high surgical risk who have been non-responders to currently adopted conservative therapies.